Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Price Target at $8.24

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received an average rating of “Hold” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.24.

ZNTL has been the subject of a number of analyst reports. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group reduced their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, HC Wainwright decreased their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th.

Insider Activity

In related news, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC grew its stake in Zentalis Pharmaceuticals by 84.8% in the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock worth $96,000 after acquiring an additional 11,997 shares during the period. Exchange Traded Concepts LLC increased its stake in Zentalis Pharmaceuticals by 195.3% in the third quarter. Exchange Traded Concepts LLC now owns 45,506 shares of the company’s stock valued at $167,000 after purchasing an additional 30,098 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Zentalis Pharmaceuticals by 44.3% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company’s stock worth $250,000 after buying an additional 20,848 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the last quarter. Finally, Carson Advisory Inc. boosted its stake in Zentalis Pharmaceuticals by 55.8% in the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after buying an additional 8,800 shares during the last quarter.

Zentalis Pharmaceuticals Stock Up 2.1 %

NASDAQ ZNTL opened at $2.48 on Wednesday. The stock has a market capitalization of $176.72 million, a P/E ratio of -1.00 and a beta of 1.81. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $18.07. The firm has a 50-day moving average price of $2.60 and a 200 day moving average price of $3.09.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.